ProCE Banner Activity

Available and Emerging Treatment Options in FLT3-Mutant and IDH-Mutant AML

Slideset Download
Amir Fathi, MD, provides expert insights and guidance on the best strategies to optimize treatment for patients with FLT3-mutant or IDH-mutant AML.

Released: December 06, 2019

Expiration: December 04, 2020

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

Actinium

Boston Biomedical

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.

Partners

NCCN

ProCE Banner

Faculty Disclosure

Primary Author

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts